<DOC>
	<DOCNO>NCT02598960</DOCNO>
	<brief_summary>The purpose study evaluate safety , tolerability pharmacokinetics , pharmacodynamics , immunogenicity preliminary anti-tumor activity BMS-986156 administer alone combination nivolumab subject advance solid tumor .</brief_summary>
	<brief_title>A Study BMS-986156 Given Alone Combination With Nivolumab Subjects With Advanced Solid Tumors</brief_title>
	<detailed_description />
	<mesh_term>Nivolumab</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>For information regard BMS clinical trial participation , please visit www.BMSStudyConnect.com For Dose Escalation : Subjects previously treat advanced ( metastatic refractory ) solid tumor For Cohort Expansion : Subjects must previously treat advanced solid tumor eligible Eastern Cooperative Oncology Group ( ECOG ) performance status 0 1 Willing able provide pretreatment ontreatment fresh tumor biopsy Women childbearing potential men must use acceptable method contraception treatment 23 week treatment woman 31 week men Known central nervous system metastases central nervous system source disease Other concomitant malignancy ( exception per protocol ) Active , know suspected autoimmune disease Uncontrolled significant cardiovascular disease History active chronic hepatitis ( e.g . Hep B C ) Impaired liver bone marrow function Major surgery less 1 month start study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>